4528.T लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 11:45):

Stats
आज की मात्रा	3.19M
औसत मात्रा	2.18M
बाजार मूल्य	1 048.85B
EPS	¥0 ( 2024-01-30 )
अगली कमाई की तारीख	( ¥51.38 ) 2024-05-08
Last Dividend	¥37.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	8.71
ATR14	¥1.094 (0.05%)

मात्रा सहसंबंध

लंबा: 0.27 (neutral)

छोटा: 0.04 (neutral)

Signal:(50.934) Neutral

Ono Pharmaceutical Co., सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Ono Pharmaceutical Co., सहसंबंध - मुद्रा/वस्त्र

0.35
( neutral )

0.46
( neutral )

0.06
( neutral )

0.56
( weak )

-0.35
( neutral )

-0.22
( neutral )

Ono Pharmaceutical Co., वित्तीय

Annual	2022
राजस्व:	¥447.19B
सकल लाभ:	¥337.13B (75.39 %)
EPS:	¥230.85

FY	2022
राजस्व:	¥447.19B
सकल लाभ:	¥337.13B (75.39 %)
EPS:	¥230.85

FY	2022
राजस्व:	¥361.36B
सकल लाभ:	¥267.85B (74.12 %)
EPS:	¥162.19

FY	2021
राजस्व:	¥309.28B
सकल लाभ:	¥223.71B (72.33 %)
EPS:	¥151.11

Financial Reports:

No articles found.

Ono Pharmaceutical Co., Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥33.00 (N/A)	¥0 (N/A)	¥37.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Ono Pharmaceutical Co., Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.64 - Stable (12.82%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥6.80	2001-03-27
Last Dividend	¥37.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	41	--
Total Paid Out	¥671.50	--
Avg. Dividend % Per Year	0.00%	--
Score	4.16	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.64
Div. Directional Score	9.16	--

Next Divdend (Est)
(2024-10-14)

¥0 Estimate 0.00 %

Dividend Stability

0.09 Very Bad

Dividend Score

4.16

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8136.T	Ex Dividend Junior	2023-09-28	Annually	0.00%
7483.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
6707.T	Ex Dividend Knight	2023-09-28	Annually	0.00%
6058.T	Ex Dividend Junior	2024-02-28	Sporadic	0.00%
4733.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
3981.T	Ex Dividend Junior	2023-12-28	Annually	0.00%
3186.T	Ex Dividend Junior	2023-11-29	Annually	0.00%
2180.T	Ex Dividend Junior	2023-12-28	Annually	0.00%
9052.T	Ex Dividend Junior	2023-09-28	Annually	0.00%
7942.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.256	1.500	4.88	7.31	[0 - 0.5]
returnOnAssetsTTM	0.143	1.200	5.23	6.28	[0 - 0.3]
returnOnEquityTTM	0.166	1.500	9.26	10.00	[0.1 - 1]
payoutRatioTTM	0.291	-1.000	7.09	-7.09	[0 - 1]
currentRatioTTM	3.95	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	3.19	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.140	1.500	4.78	7.17	[0.2 - 2]
debtRatioTTM	0.00963	-1.500	9.84	-10.00	[0 - 0.6]
interestCoverageTTM	99.03	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	222.86	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	191.88	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.0109	-1.500	9.96	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.756	1.000	0.740	0.740	[0.2 - 0.8]
operatingProfitMarginTTM	0.329	1.000	5.41	5.41	[0.1 - 0.6]
cashFlowToDebtRatioTTM	12.35	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.559	0.800	9.61	7.69	[0.5 - 2]
Total Score				12.67

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	8.58	1.000	9.23	0	[1 - 100]
returnOnEquityTTM	0.166	2.50	9.53	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	191.88	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	3.48	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	222.86	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.291	1.500	7.09	-7.09	[0 - 1]
pegRatioTTM	-1.449	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.213	1.000	7.18	0	[0.1 - 0.5]
Total Score				5.64

Ono Pharmaceutical Co.,

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors. The company also provides GLACTIV and FORXIGA tablets for type 2 diabetes; FORXIGA tablets for the treatment of diabetes; ONOACT injections for tachyarrhythmia; OPALMON tablets to treat peripheral circulatory disorder; CORALAN for treatment of chronic heart failure; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONGENTYS tablets for the treatment of Parkinson's disease; PARSABIV, an intravenous injection for dialysis patients; STAYBLA tablets for overactive bladder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as RECALBON tablets for osteoporosis. In addition, it is developing products for esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.